215 related articles for article (PubMed ID: 19558681)
1. Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis.
Mills EJ; Perri D; Cooper C; Nachega JB; Wu P; Tleyjeh I; Phillips P
Ann Clin Microbiol Antimicrob; 2009 Jun; 8():23. PubMed ID: 19558681
[TBL] [Abstract][Full Text] [Related]
2. Treatment of invasive candidal infections: systematic review and meta-analysis.
Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
[TBL] [Abstract][Full Text] [Related]
3. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
Cortegiani A; Russotto V; Maggiore A; Attanasio M; Naro AR; Raineri SM; Giarratano A
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD004920. PubMed ID: 26772902
[TBL] [Abstract][Full Text] [Related]
4. Systemic antifungal therapy for oesophageal candidiasis - systematic review and meta-analysis of randomized controlled trials.
Mwassi HA; Yahav D; Ayada G; Matsri S; Margalit I; Shargian L; Bishara J; Atamna A
Int J Antimicrob Agents; 2022 Jun; 59(6):106590. PubMed ID: 35427762
[TBL] [Abstract][Full Text] [Related]
5. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.
Blyth CC; Hale K; Palasanthiran P; O'Brien T; Bennett MH
Cochrane Database Syst Rev; 2010 Feb; 2010(2):CD006343. PubMed ID: 20166083
[TBL] [Abstract][Full Text] [Related]
6. Anidulafungin versus fluconazole for invasive candidiasis.
Reboli AC; Rotstein C; Pappas PG; Chapman SW; Kett DH; Kumar D; Betts R; Wible M; Goldstein BP; Schranz J; Krause DS; Walsh TJ;
N Engl J Med; 2007 Jun; 356(24):2472-82. PubMed ID: 17568028
[TBL] [Abstract][Full Text] [Related]
7. [Potential of anidulafungin in hematological patients].
Vázquez López L; Ruiz Camps I
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():44-50. PubMed ID: 19572434
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis.
Demir KK; Butler-Laporte G; Del Corpo O; Ekmekjian T; Sheppard DC; Lee TC; Cheng MP
Mycoses; 2021 Sep; 64(9):1098-1110. PubMed ID: 33894072
[TBL] [Abstract][Full Text] [Related]
9. Echinocandins vs. amphotericin B against invasive candidiasis in children and neonates: A meta-analysis of randomized controlled trials.
Chen YH; Cheng IL; Lai CC; Tang HJ
Int J Antimicrob Agents; 2019 Jun; 53(6):789-794. PubMed ID: 30831231
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
Kullberg BJ; Sobel JD; Ruhnke M; Pappas PG; Viscoli C; Rex JH; Cleary JD; Rubinstein E; Church LW; Brown JM; Schlamm HT; Oborska IT; Hilton F; Hodges MR
Lancet; 2005 Oct 22-28; 366(9495):1435-42. PubMed ID: 16243088
[TBL] [Abstract][Full Text] [Related]
11. Anidulafungin: a new echinocandin with a novel profile.
Vazquez JA
Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
[TBL] [Abstract][Full Text] [Related]
12. Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines.
De Rosa FG; Motta I; Corcione S; Cattel F; Di Perri G; D'Avolio A
Infez Med; 2014 Jun; 22(2):107-11. PubMed ID: 24955796
[TBL] [Abstract][Full Text] [Related]
13. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies.
Kontoyiannis DP; Bassetti M; Nucci M; Capparella MR; Yan JL; Aram J; Hogan PA
Mycoses; 2017 Oct; 60(10):663-667. PubMed ID: 28597967
[TBL] [Abstract][Full Text] [Related]
14. Anidulafungin, a new echinocandin: effectiveness and tolerability.
Menichetti F
Drugs; 2009; 69 Suppl 1():95-7. PubMed ID: 19877741
[TBL] [Abstract][Full Text] [Related]
15. Anidulafungin in the treatment of patients with invasive candidiasis.
Kett DH; Cubillos GF
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S99-S102. PubMed ID: 19013348
[TBL] [Abstract][Full Text] [Related]
16. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
Kett DH; Shorr AF; Reboli AC; Reisman AL; Biswas P; Schlamm HT
Crit Care; 2011; 15(5):R253. PubMed ID: 22026929
[TBL] [Abstract][Full Text] [Related]
17. Antifungals in systemic neonatal candidiasis.
Frattarelli DA; Reed MD; Giacoia GP; Aranda JV
Drugs; 2004; 64(9):949-68. PubMed ID: 15101785
[TBL] [Abstract][Full Text] [Related]
18. Azoles versus conventional amphotericin B for the treatment of candidemia: A meta-analysis of randomized controlled trials.
Osa S; Tashiro S; Igarashi Y; Watabe Y; Liu X; Enoki Y; Taguchi K; Mayumi T; Miyazaki Y; Takesue Y; Matsumoto K
J Infect Chemother; 2020 Nov; 26(11):1232-1236. PubMed ID: 32828679
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.
Wang JF; Xue Y; Zhu XB; Fan H
Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):651-9. PubMed ID: 25502737
[TBL] [Abstract][Full Text] [Related]
20. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
